S&P 500   5,027.65 (+1.22%)
DOW   38,365.48 (+1.00%)
QQQ   420.44 (+1.40%)
AAPL   166.49 (+0.90%)
MSFT   401.93 (+0.70%)
META   486.40 (+1.11%)
GOOGL   157.22 (+2.03%)
AMZN   177.76 (+1.79%)
TSLA   141.77 (-3.59%)
NVDA   795.17 (+4.35%)
AMD   148.91 (+1.55%)
NIO   4.02 (+5.79%)
BABA   70.68 (+2.33%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.90 (+2.93%)
GE   150.98 (+1.97%)
CGC   7.97 (+0.50%)
DIS   112.87 (+0.23%)
AMC   3.37 (+6.65%)
PFE   26.39 (+1.50%)
PYPL   63.39 (+1.73%)
XOM   121.25 (+1.14%)
S&P 500   5,027.65 (+1.22%)
DOW   38,365.48 (+1.00%)
QQQ   420.44 (+1.40%)
AAPL   166.49 (+0.90%)
MSFT   401.93 (+0.70%)
META   486.40 (+1.11%)
GOOGL   157.22 (+2.03%)
AMZN   177.76 (+1.79%)
TSLA   141.77 (-3.59%)
NVDA   795.17 (+4.35%)
AMD   148.91 (+1.55%)
NIO   4.02 (+5.79%)
BABA   70.68 (+2.33%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.90 (+2.93%)
GE   150.98 (+1.97%)
CGC   7.97 (+0.50%)
DIS   112.87 (+0.23%)
AMC   3.37 (+6.65%)
PFE   26.39 (+1.50%)
PYPL   63.39 (+1.73%)
XOM   121.25 (+1.14%)
S&P 500   5,027.65 (+1.22%)
DOW   38,365.48 (+1.00%)
QQQ   420.44 (+1.40%)
AAPL   166.49 (+0.90%)
MSFT   401.93 (+0.70%)
META   486.40 (+1.11%)
GOOGL   157.22 (+2.03%)
AMZN   177.76 (+1.79%)
TSLA   141.77 (-3.59%)
NVDA   795.17 (+4.35%)
AMD   148.91 (+1.55%)
NIO   4.02 (+5.79%)
BABA   70.68 (+2.33%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.90 (+2.93%)
GE   150.98 (+1.97%)
CGC   7.97 (+0.50%)
DIS   112.87 (+0.23%)
AMC   3.37 (+6.65%)
PFE   26.39 (+1.50%)
PYPL   63.39 (+1.73%)
XOM   121.25 (+1.14%)
S&P 500   5,027.65 (+1.22%)
DOW   38,365.48 (+1.00%)
QQQ   420.44 (+1.40%)
AAPL   166.49 (+0.90%)
MSFT   401.93 (+0.70%)
META   486.40 (+1.11%)
GOOGL   157.22 (+2.03%)
AMZN   177.76 (+1.79%)
TSLA   141.77 (-3.59%)
NVDA   795.17 (+4.35%)
AMD   148.91 (+1.55%)
NIO   4.02 (+5.79%)
BABA   70.68 (+2.33%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.90 (+2.93%)
GE   150.98 (+1.97%)
CGC   7.97 (+0.50%)
DIS   112.87 (+0.23%)
AMC   3.37 (+6.65%)
PFE   26.39 (+1.50%)
PYPL   63.39 (+1.73%)
XOM   121.25 (+1.14%)

Avidity Biosciences (RNA) Competitors

$24.63
+1.90 (+8.36%)
(As of 02:40 PM ET)

RNA vs. PTCT, GLPG, GERN, AMPH, CPRX, SNDX, SDGR, MRVI, GPCR, and NAMS

Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include PTC Therapeutics (PTCT), Galapagos (GLPG), Geron (GERN), Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), Syndax Pharmaceuticals (SNDX), Schrödinger (SDGR), Maravai LifeSciences (MRVI), Structure Therapeutics (GPCR), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.

Avidity Biosciences vs.

Avidity Biosciences (NASDAQ:RNA) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation.

Avidity Biosciences presently has a consensus price target of $36.33, suggesting a potential upside of 52.02%. PTC Therapeutics has a consensus price target of $33.53, suggesting a potential upside of 30.02%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Avidity Biosciences is more favorable than PTC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
PTC Therapeutics
5 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
1.85

PTC Therapeutics received 405 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 64.11% of users gave Avidity Biosciences an outperform vote while only 62.10% of users gave PTC Therapeutics an outperform vote.

CompanyUnderperformOutperform
Avidity BiosciencesOutperform Votes
134
64.11%
Underperform Votes
75
35.89%
PTC TherapeuticsOutperform Votes
539
62.10%
Underperform Votes
329
37.90%

Avidity Biosciences has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

In the previous week, PTC Therapeutics had 5 more articles in the media than Avidity Biosciences. MarketBeat recorded 8 mentions for PTC Therapeutics and 3 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.75 beat PTC Therapeutics' score of 0.91 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avidity Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
PTC Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

PTC Therapeutics has a net margin of -66.82% compared to Avidity Biosciences' net margin of -2,219.87%. PTC Therapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Avidity Biosciences-2,219.87% -39.74% -34.98%
PTC Therapeutics -66.82%N/A -32.06%

Avidity Biosciences has higher earnings, but lower revenue than PTC Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avidity Biosciences$9.56M199.30-$212.22M-$2.90-8.24
PTC Therapeutics$937.82M2.13-$626.60M-$8.36-3.12

Summary

Avidity Biosciences beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNA vs. The Competition

MetricAvidity BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.91B$6.27B$4.64B$7.31B
Dividend YieldN/A3.10%5.46%3.98%
P/E Ratio-8.247.92181.0616.24
Price / Sales199.30302.982,596.1880.96
Price / CashN/A19.0131.1927.20
Price / Book3.545.594.594.45
Net Income-$212.22M$136.96M$99.84M$212.71M
7 Day Performance-0.04%-0.53%108.82%-0.25%
1 Month Performance0.84%-6.92%106.69%-1.31%
1 Year Performance46.45%1.55%132.80%5.49%

Avidity Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTCT
PTC Therapeutics
3.4487 of 5 stars
$25.29
-1.5%
$33.53
+32.6%
-54.1%$1.94B$937.82M-3.03988Upcoming Earnings
News Coverage
GLPG
Galapagos
0.4421 of 5 stars
$29.49
-1.0%
$34.50
+17.0%
-25.1%$1.94B$259.40M-12.881,123Analyst Report
GERN
Geron
3.3931 of 5 stars
$3.58
+3.8%
$5.33
+49.0%
+38.2%$1.96B$240,000.00-10.85141Positive News
AMPH
Amphastar Pharmaceuticals
4.8142 of 5 stars
$40.90
+0.3%
$66.00
+61.4%
-8.7%$1.97B$644.40M15.851,761Analyst Revision
Positive News
CPRX
Catalyst Pharmaceuticals
4.9892 of 5 stars
$15.54
+1.0%
$26.43
+70.1%
-8.2%$1.83B$398.20M25.48167Positive News
SNDX
Syndax Pharmaceuticals
2.9183 of 5 stars
$21.28
-1.6%
$34.42
+61.7%
-3.3%$1.81B$139.71M-7.19184
SDGR
Schrödinger
3.5339 of 5 stars
$24.76
-3.1%
$43.50
+75.7%
-17.9%$1.79B$216.67M39.30867Positive News
MRVI
Maravai LifeSciences
4.2538 of 5 stars
$8.14
+0.4%
$11.56
+42.0%
-49.5%$2.05B$288.95M-9.04650
GPCR
Structure Therapeutics
1.6586 of 5 stars
$37.82
+0.5%
$85.71
+126.6%
+45.4%$1.76BN/A-45.5793
NAMS
NewAmsterdam Pharma
3.246 of 5 stars
$19.50
-1.2%
$33.25
+70.5%
+28.4%$1.74B$14.09M0.0029Positive News
High Trading Volume

Related Companies and Tools

This page (NASDAQ:RNA) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners